Global Emerging Markets Group

Global Emerging Markets Group (GEM) is a $3.4 billion alternative investment group that manages a diverse set of investment vehicles focused on emerging markets and high-growth sectors globally. Founded in 1991, the firm is a prominent provider of flexible equity financing solutions, such as Share Subscription Facilities (SSFs), which are frequently utilized by small-to-mid-cap biotechnology and life sciences companies. These financial instruments allow companies to draw down capital as needed to fund clinical trials, research and development, and corporate expansion. GEM has a broad geographic footprint with offices in Paris, New York, and Luxembourg, having completed over 530 transactions in 75 countries. While not a therapeutic developer itself, GEM acts as a critical financial partner for the global healthcare innovation ecosystem.